Patents by Inventor Timothy ALEFANTIS

Timothy ALEFANTIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HYBRID MULTIVALENT INFLUENZA VACCINES COMPRISING HEMAGGLUTININ AND NEURAMINIDASE AND METHODS OF USING THE SAME
    Publication number: 20240285750
    Abstract: Disclosed herein are hybrid multivalent vaccine or immunogenic compositions comprising (i) one or more influenza virus proteins selected from one or more influenza virus hemagglutinin (HA) proteins, one or more influenza virus neuraminidase (NA) proteins, or a combination thereof; and (ii) one or more ribonucleic acid molecules encoding one or more influenza virus proteins selected from one or more influenza virus HA proteins, one or more influenza virus NA proteins, or a combination thereof. Also disclosed are methods of using the vaccine or immunogenic compositions.
    Type: Application
    Filed: May 2, 2024
    Publication date: August 29, 2024
    Inventors: Timothy ALEFANTIS, Mario BARRO, Saranya SRIDHAR, Thorsten VOGEL, William WARREN
  • MULTIVALENT INFLUENZA VACCINES COMPRISING RECOMBINANT HEMAGGLUTININ AND NEURAMINIDASE AND METHODS OF USING THE SAME
    Publication number: 20240277828
    Abstract: Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.
    Type: Application
    Filed: May 2, 2024
    Publication date: August 22, 2024
    Inventors: Timothy ALEFANTIS, Mario BARRO, Anthony BYERS, Guadalupe CORTES-GARCIA, Philippe-Alexandre GILBERT, Harold KLEANTHOUS, Armaghan NAIK, Konstantin PUGACHEV, Saranya SRIDHAR, Thorsten VOGEL, William WARREN
  • MULTIVALENT INFLUENZA VACCINES
    Publication number: 20240269258
    Abstract: Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.
    Type: Application
    Filed: April 5, 2024
    Publication date: August 15, 2024
    Inventors: Timothy ALEFANTIS, Mario BARRO, Anthony BYERS, Philip DAVIDSON, Maryann GIEL-MOLONEY, Philippe-Alexandre GILBERT, Harold KLEANTHOUS, Armaghan NAIK, Konstantin PUGACHEV, Saranya SRIDHAR, William WARREN, Konstantin ZELDOVICH
  • EXPRESSION AND CONFORMATIONAL ANALYSIS OF ENGINEERED INFLUENZA HEMAGGLUTININ
    Publication number: 20170121373
    Abstract: The present invention provides, among other things, compositions and methods for analyzing the expression and conformation of engineered influenza hemagglutinin In particular, the present invention provides methods of screening in silico designed HA antigens using neutralizing antibody panels specific to conserved epitopes. In some embodiments, the HAs are down selected for inclusion in universal influenza vaccines based upon their binding to neutralizing antibody panels in immunostaining assays.
    Type: Application
    Filed: May 29, 2015
    Publication date: May 4, 2017
    Inventors: Guadalupe CORTES-GARCIA, Timothy ALEFANTIS, Mark PARRINGTON